Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia

  1. Pérez de Isla, L.
  2. Ray, K.K.
  3. Watts, G.F.
  4. Santos, R.D.
  5. Alonso, R.
  6. Muñiz-Grijalvo, O.
  7. Diaz-Diaz, J.L.
  8. Badimon, L.
  9. Catapano, A.L.
  10. Mata, P.
Aldizkaria:
Atherosclerosis

ISSN: 1879-1484,  0021-9150

Argitalpen urtea: 2019

Alea: 286

Orrialdeak: 40-45

Mota: Artikulua

DOI: 10.1016/J.ATHEROSCLEROSIS.2019.05.003 GOOGLE SCHOLAR
Datuen iturria: Scopus